While the majority of CRPC remains AR-positive and presents an adenocarcinoma phenotype, more potent AR pathway inhibitor (ARPI) treatment often induced AR negative neuroendocrine prostate cancer (NEPC) or double-negative prostate tumours (DNPC) accounting for ~20% of CRPC (8–11). This evidence concerns the gene AR and adenocarcinoma.